Panic Disorder

Background

- 1. Definition
 - Recurrent acute attacks of anxiety, fear, or discomfort which peak within seconds to minutes and are associated with overwhelming feelings of dread and autonomic activation
 - Persistent worry, avoidance behaviors, limiting social interaction for fear of repeat attack

Pathophysiology²

- 1. Pathology of disease
 - Current area of active neuroanatomic research regarding anatomic brain centers (cortex vs brain stem) and neurotransmitters involved
 - Recent psychosocial stressors associated with onset of first attack

2. Incidence, prevalence

- o 12 month prevalence: 3.2% women, 1.3% men
- o Lifetime prevalence: 5% women, 2% men
- o Bimodal distribution: peaks in late adolescence and 30s
- Single attacks occur up to 30-35% people (not meeting DSM-IV criteria for diagnosis of panic disorder)
- o Most common anxiety disorder in primary care (about 8% patients)

3. Risk factors⁵

- Genetic: Monozygotic twins, first degree relatives with panic disorders (40% heritability)
- o Major life stressors in last 12 months
- o Hx of sexual or physical abuse in childhood
- o Anxious temperament or anxiety sensitivity
- o 90% will have additional psychiatric disorder (ex: major depression, general anxiety disorder, agoraphobia, PTSD, bipolar disorder, alcohol abuse)

4. Morbidity/ mortality

- o Relapsing, remitting: 20% of patients have a chronic disease course
- o 70% patients clinically depressed or with agoraphobia
- o 20% patients attempt suicide
- Associated with increased risk of coronary heart disease (Women's Health Initiative)
- o 50% recover with appropriate treatment

Diagnostics

- 1. History
 - o HPI
 - Description of attack:
 - Chest pain, hyperventilation, IBS, unexplained dizziness/palpitations
 - Symptoms peak at 5-10 minutes, subside slowly over 30-60 min

Panic Disorder Page 1 of 5 11.1.10

- If recurrent attacks the patient may develop extreme anxiety regarding potential of future attacks
- Evaluation for safety of patient (e.g. suicidal ideation)
- Severity of functional impairment
- o PMH:
 - Past psychiatric hx
 - Personal hx (major life events/stressors)
- Medications:
 - Stimulants (cocaine, OTC pseudoephedrine, caffeine)
 - Alcohol abuse
- 2. Physical examination
 - Nonspecific findings
 - o During panic attack: tachycardia, sweating, tremor, air hunger
- 3. Diagnostic testing
 - Laboratory Evaluation
 - None required for diagnosis
 - Evaluating for other causes: BMP, TSH, EKG, depression screen, alcohol screen,
 - o Diagnostic Imaging
 - None required for diagnosis
 - Consider: Echo for mitral valve prolapsed

4. DSM-IV-TR Diagnostic Criteria

- Discrete period of intense fear or discomfort with 4 or more of following symptoms
- o Develop abruptly, peak within 10 minutes of onset
 - Palpitations, pounding heart, accelerated heart rate
 - Sweating
 - Trembling or shaking
 - Sensations of shortness of breath or smothering, air hunger
 - Sensation of choking
 - Chest pain or discomfort
 - Nausea or abdominal distress
 - Feeling dizzy, unsteady, lightheaded, or faint
 - Derealization (feelings of unreality) or depersonalization (being detached from oneself)
 - Fear of losing control or going crazy
 - Fear of dying
 - Paresthesias (numbness or tingling sensations)
 - Chills or hot flushes

Differential Diagnosis

- 1. Key Differential Diagnosis
 - o Hyperthyroidism
 - o Caffeine use
 - o Stimulant use or abuse
 - Partial complex seizures
 - Temporal lobe epilepsy

- o Asthma
- Cardiac arrhythmias
- Alcohol withdrawal
- o Pheochromocytoma
- Corticosteroid treatment

2. Extensive Differential Diagnosis

- Psych: depression, schizophrenia, mania, atypical psychosis, adjustment disorder, OCD, PTSD, phobia
- o Social: substance abuse (cocaine, stimulants, alcohol)
- Neuro: cerebral neoplasm, trauma, postconcussive syndrome, migraine, encephalitis, multiple sclerosis, epilepsy, subarachnoid hemorrhage, partial seizures
- o Cardio: PSVT or other cardiac arrythmias
- o Endocrine: hyperthyroidism, pheochromocytoma, pituitary disease
- o Inflammatory: RA, temporal arteritis, SLE or other autoimmune disease
- Toxicity: vasopressors, caffeine, PCN, cannabis, mercury, alcohol and drug withdrawal, amphetamines, sympathomimetic drugs, organophosphates, aspirin
- Drugs with panic attacks as potential side effect: buspirone, estrogens, levodopa, ondansetron, supatripan

Therapeutics

- 1. Treatment overview
 - Indicated when symptoms interfere with functioning or cause significant distress
 - Effective treatment aimed at reducing frequency/intensity of panic attacks
 AND reducing anticipatory anxiety and agoraphobic avoidance
 - Consists of supportive and explanatory model (it is not "all in patient's head)
 - o Treat underlying mood disorder if present

2. Acute Treatment

- Antidepressants
 - SSRIs: Sertraline, paroxetine, fluoxetine, citalopram, escitalopram
 - Tricyclic antidepressants: imipramine, clomipramine
 - Efficacy may take 4-6 weeks, full response may take 8-12 weeks
- Benzodiazepines
 - Preferentially used for short term acute treatment
 - First line for acute crisis, especially for patients at risk for social or operational dysfunction
 - Ex: alprazolam, clonazepam, diazepam, lorazepam, oxazepam
 - Adverse effects:
 - Sedation
 - Increased falls in elderly
 - Respiratory depression
 - Hypotension
 - Physical dependence (in long term use)
 - Insomnia
 - Constipation

- Withdrawal: rebound anxiety, insomnia, nausea, vomiting, irritability, delirium, rarely seizures
 - May occur after abrupt or rapid discontinuation
 - More likely with short-acting benzodiazepines
- Drugs relatively ineffective for panic disorder
 - Bupropion, trazodone, amoxapine, clonidine
 - Beta blockers insufficient as primary treatment
 - May reduce physical symptoms such as tremor and tachycardia
- 3. Further Management
 - Cognitive behavioral therapy (CBT)
 - Appears to be as effective as pharmacotherapy
 - Combination of CBT and antidepressant more effective than either treatment alone
 - Components: education about anxiety, cognitive intervention, relaxation, controlled breathing, exposure techniques
 - o Increasing physical activity
 - Aerobic exercise beneficial
- 4. Long Term Care
 - o Regular clinic visits
 - o Collaborative care: CBT, family therapy
 - Continue medications at least 6 months, do not stop medications at times of high stress

Follow Up

- 1. Return to Office
 - o Therapeutic alliance very important, regularly scheduled visits helpful
 - o Earlier follow up: medication dose change, triggers, failure of therapy
- 2. Refer to Specialist
 - o Psych consult if patient needing >6mg alprazolam per day
 - Collaborative care improves outcomes
- 3. Admit to Hospital
 - o If associated with acute suicidal or homicidal ideation
 - o If inpatient detoxification required for substance use disorder

Prognosis

- 1. Functional morbidity, disabling, especially when complicated by agoraphobia
- 2. 50% recover with treatment, 30-50% relapse
- 3. Chronic cases characterized by remissions and exacerbations

Prevention

- 1. Consider counseling after initial panic attack to try to reduce the development into panic disorder
- 2. Identify patients at risk based on hx of abuse and implement CBT early

Patient Education

1. Panic Disorder: Panic Attacks and Agoraphobia at

http://familydoctor.org/online/famdocen/home/common/mentalhealth/anxiety/137.html

Evidence-Based Inquiry

1. What are the most practical primary care screens for post-traumatic stress disorder?

References

- 1. Katon WJ. Panic disorder. NEJM 2006; 354:2360-7.
- 2. Ham P, Waters DB, Oliver MN. Treatment of panic disorder. Am Fam Phys 2005; 71:733-739.
- 3. Roy-Byrne PB, Craske MG, Stein MB. Panic disorder. Lancet 2006; 368: 1023-32.
- 4. Strupe PA, Weissman AM. Clinical Inquiries. What are the effective treatments of panic disorder? J Fam Pract 2002; 51: 831.

Author: Nicole Gesik, MD, Oregon Health & Sciences University

Editor: Robert Marshall, MD, MPH, Capt MC USN, Puget Sound Family Medicine Residence, Naval Hospital, Bremerton, WA